Surgical prophylaxis in pancreatoduodenectomy: Is cephalosporin still the drug of choice in patients with biliary stents in situ?

IF 2.8 2区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Kai Chee Hung , Shimin Jasmine Chung , Andrea Layhoon Kwa , Winnie Hui Ling Lee , Ye Xin Koh , Brian K.P. Goh
{"title":"Surgical prophylaxis in pancreatoduodenectomy: Is cephalosporin still the drug of choice in patients with biliary stents in situ?","authors":"Kai Chee Hung ,&nbsp;Shimin Jasmine Chung ,&nbsp;Andrea Layhoon Kwa ,&nbsp;Winnie Hui Ling Lee ,&nbsp;Ye Xin Koh ,&nbsp;Brian K.P. Goh","doi":"10.1016/j.pan.2024.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Universal surgical prophylaxis for pancreatoduodenectomy (PD) is practiced, with cephalosporins recommended in most guidelines. Recent studies suggest piperacillin-tazobactam (PTZ) prophylaxis in biliary-stented patients is superior in preventing surgical site infections (SSIs). This study aims to refine surgical prophylaxis recommendations based on the local microbial profile and evaluate the clinical outcomes of biliary-stented compared with non-stented patients.</p></div><div><h3>Methods</h3><p>This was a retrospective study of all consecutive PD patients at Singapore General Hospital between January 2013 to December 2019. The primary outcome was post-operative SSI rates. Secondary outcomes included rates of ceftriaxone-resistant <em>Klebsiella pneumoniae, Escherichia coli,</em> and <em>Enterococcus</em> species from intraoperative bile cultures and 30-day mortality.</p></div><div><h3>Results</h3><p>There were 130 biliary-stented and 211 non-stented patients included. Majority of biliary-stented patients received ceftriaxone ± metronidazole prophylaxis (83/130, 63.8 %) while 30/130 (23.8 %) received PTZ. Most non-stented patients received ceftriaxone ± metronidazole prophylaxis (163/211, 77.3 %). Between biliary-stented and non-stented patients, post-operative SSIs (40.8 % vs 38.4 %, p = 0.662), and 30-day mortality rates (1.5 % vs 1.4 %, p = 1.000) were comparable. The adjusted odds of post-operative SSIs was significantly lower in biliary-stented patients prescribed PTZ as compared to non-PTZ prophylaxis (0.29, 95 % CI (0.10–0.79), p = 0.015). Ceftriaxone-resistant <em>Klebsiella</em> spp. and/or <em>Escherichia coli</em> (27.6 % vs 3.8 %, p &lt; 0.001) as well as <em>Enterococcus species</em> (46.1 % vs 11.5 %, p &lt; 0.001), were more prevalent in intraoperative bile cultures of biliary-stented patients, while frequencies in non-stented patients were low.</p></div><div><h3>Conclusion</h3><p>PTZ prophylaxis effectively reduced SSIs in stented patients post-pancreatoduodenectomy. Based on the local microbial profile, ceftriaxone prophylaxis may be used for prophylaxis in non-stented patients.</p></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1424390324006847","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Universal surgical prophylaxis for pancreatoduodenectomy (PD) is practiced, with cephalosporins recommended in most guidelines. Recent studies suggest piperacillin-tazobactam (PTZ) prophylaxis in biliary-stented patients is superior in preventing surgical site infections (SSIs). This study aims to refine surgical prophylaxis recommendations based on the local microbial profile and evaluate the clinical outcomes of biliary-stented compared with non-stented patients.

Methods

This was a retrospective study of all consecutive PD patients at Singapore General Hospital between January 2013 to December 2019. The primary outcome was post-operative SSI rates. Secondary outcomes included rates of ceftriaxone-resistant Klebsiella pneumoniae, Escherichia coli, and Enterococcus species from intraoperative bile cultures and 30-day mortality.

Results

There were 130 biliary-stented and 211 non-stented patients included. Majority of biliary-stented patients received ceftriaxone ± metronidazole prophylaxis (83/130, 63.8 %) while 30/130 (23.8 %) received PTZ. Most non-stented patients received ceftriaxone ± metronidazole prophylaxis (163/211, 77.3 %). Between biliary-stented and non-stented patients, post-operative SSIs (40.8 % vs 38.4 %, p = 0.662), and 30-day mortality rates (1.5 % vs 1.4 %, p = 1.000) were comparable. The adjusted odds of post-operative SSIs was significantly lower in biliary-stented patients prescribed PTZ as compared to non-PTZ prophylaxis (0.29, 95 % CI (0.10–0.79), p = 0.015). Ceftriaxone-resistant Klebsiella spp. and/or Escherichia coli (27.6 % vs 3.8 %, p < 0.001) as well as Enterococcus species (46.1 % vs 11.5 %, p < 0.001), were more prevalent in intraoperative bile cultures of biliary-stented patients, while frequencies in non-stented patients were low.

Conclusion

PTZ prophylaxis effectively reduced SSIs in stented patients post-pancreatoduodenectomy. Based on the local microbial profile, ceftriaxone prophylaxis may be used for prophylaxis in non-stented patients.

胰十二指肠切除术的手术预防:头孢菌素仍是原位胆道支架患者的首选药物吗?
背景胰十二指肠切除术(PD)采用了普遍的手术预防措施,大多数指南都推荐使用头孢菌素类药物。最近的研究表明,哌拉西林-他唑巴坦(PTZ)对胆道支架患者的预防性治疗在预防手术部位感染(SSI)方面效果更佳。本研究旨在根据当地的微生物情况完善手术预防建议,并评估与未进行纤支镜手术的患者相比,进行纤支镜手术的患者的临床效果。方法这是一项回顾性研究,研究对象是新加坡中央医院在2013年1月至2019年12月期间连续接受纤支镜手术的所有患者。主要结果是术后 SSI 感染率。次要结果包括术中胆汁培养的耐头孢曲松肺炎克雷伯菌、大肠埃希菌和肠球菌感染率以及 30 天死亡率。大多数胆道支架患者接受头孢曲松和甲硝唑预防治疗(83/130,63.8%),30/130(23.8%)接受 PTZ 治疗。大多数未做胆囊造影的患者接受头孢曲松±甲硝唑预防治疗(163/211,77.3%)。胆道支架患者和非支架患者的术后 SSI(40.8% vs 38.4%,p = 0.662)和 30 天死亡率(1.5% vs 1.4%,p = 1.000)相当。与未使用 PTZ 预防措施的患者相比,使用 PTZ 的胆道支架患者术后 SSI 的调整后几率明显降低(0.29,95 % CI (0.10-0.79),p = 0.015)。耐头孢曲松的克雷伯菌属和/或大肠埃希菌(27.6 % vs 3.8 %,p <0.001)以及肠球菌属(46.1 % vs 11.5 %,p <0.001)在胆道支架患者的术中胆汁培养中更为普遍,而在非支架患者中发生率较低。根据当地的微生物情况,头孢曲松可用于非支架患者的预防性治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pancreatology
Pancreatology 医学-胃肠肝病学
CiteScore
7.20
自引率
5.60%
发文量
194
审稿时长
44 days
期刊介绍: Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信